Diabetes Monotherapies versus Metformin-Based Combination Therapy for the Treatment of Type 2 Diabetes

References

• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701. doi:10.2337/dci18-0033
   PubMed Web of Science ®Google Scholar
• Haneda M, Noda M, Origasa H, et al. Japanese clinical practice guidelines for diabetes 2016. J Diabetes Investig. 2018;9(3):657–697.
   PubMed Web of Science ®Google Scholar
• Kim MK, Ko S-H, Kim B-Y, et al. 2019 clinical practice guidelines for type 2 diabetes mellitus in Korea. Diabetes Metab J. 2019;43(4):398–406. doi:10.4093/dmj.2019.0137
   PubMed Web of Science ®Google Scholar
• Hong Kong reference framework for diabetes care for adults in primary care settings. 2018. Available from: https://www.fhb.gov.hk/pho/english/resource/files/RF_DM_full.pdf. Accessed July 13, 2021.
   Google Scholar
• Diabetes Association of the Republic of China (Taiwan). Executive summary of the DAROC clinical practice guidelines for diabetes care - 2018. J Formos Med Assoc. 2019;119(2):577–586. doi:10.1016/j.jfma.2019.02.016
   PubMed Web of Science ®Google Scholar
• Jia W, Weng J, Zhu D, et al. Standards of medical care for type 2 diabetes in China 2019. Diabetes Metab Res Rev. 2019;35:e3158.
   PubMed Web of Science ®Google Scholar
• Khunti S, Khunti K, Seidu S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Ther Adv Endocrinol Metab. 2019;10:204201881984469. doi:10.1177/2042018819844694
   Web of Science ®Google Scholar
• Cahn A, Cefalu WT. Clinical considerations for use of initial combination therapy in type 2 diabetes. Diabetes Care. 2016;39(Supplement 2):S137–S145. doi:10.2337/dcS15-3007
   PubMed Web of Science ®Google Scholar
• Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the diabetes & aging study). Diabetes Care. 2019;42(3):416–426. doi:10.2337/dc17-1144
   PubMed Web of Science ®Google Scholar
• Cersosimo E, Johnson EL, Chovanes C, Skolnik N. Initiating therapy in patients newly diagnosed with type 2 diabetes: combination therapy vs a stepwise approach. Diabetes Obes Metab. 2018;20(3):497–507. doi:10.1111/dom.13108
   PubMed Web of Science ®Google Scholar
• Chin KL, Ofori-Asenso R, Si S, et al. Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes. Sci Rep. 2019;9(1):3256. doi:10.1038/s41598-019-40191-8
   PubMed Web of Science ®Google Scholar
• Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2014;16(5):410–417. doi:10.1111/dom.12233
   PubMed Web of Science ®Google Scholar
• Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016;164(11):740–751. doi:10.7326/M15-2650
   PubMed Web of Science ®Google Scholar
• Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab. 2014;16(1):30–37. doi:10.1111/dom.12174
   PubMed Web of Science ®Google Scholar
• Pinto LC, Rados DV, Remonti LR, et al. Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis. Diabetol Metab Syndr. 2015;7(Suppl 1):A58. doi:10.1186/1758-5996-7-S1-A58
   PubMed Web of Science ®Google Scholar
• Cai X, Gao X, Yang W, Han X, Ji JL. Efficacy and safety of initial combination therapy in treatment-naïve type 2 diabetes patients: a systematic review and meta-analysis. Diabetes Ther. 2018;9(5):1995–2014. doi:10.1007/s13300-018-0493-2
   PubMed Web of Science ®Google Scholar
• Milder TY, Stocker SL, Shaheed CA, et al. Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes: a systematic review and meta-analysis. J Clin Med. 2019;8:45. doi:10.3390/jcm8010045
   PubMed Web of Science ®Google Scholar
• Wang Z, Sun J, Han R, et al. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;20(1):113–120. doi:10.1111/dom.13047
   PubMed Web of Science ®Google Scholar
• Mishriky BM, Tanenberg RJ, Sewell KA, Cummings DM. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 2018;44(2):112–120. doi:10.1016/j.diabet.2018.01.017
   PubMed Web of Science ®Google Scholar
• Li J, Gong Y, Li C, Lu Y, Liu Y, Shao Y. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus A meta-analysis. Medicine. 2017;27:e7201.
   Web of Science ®Google Scholar
• Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;4:CD002967.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668–2675. doi:10.1001/jama.2014.15298
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41(2):255–323.
   PubMed Web of Science ®Google Scholar
• American Association of Clinical Endocrinologists. Comprehensive type 2 diabetes management algorithm (2019) - executive summary. 2019. Available from: https://www.aace.com/disease-state-resources/diabetes/clinical-practice-uidelines-treatment-algorithms/comprehensive. Accessed February 14, 2020.
   Google Scholar
• Cheng AY, Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction. Can J Diabetes. 2013;37(Suppl 1):S1–S3. doi:10.1016/j.jcjd.2013.01.009
   PubMed Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63(2):221–228. doi:10.1007/s00125-019-05039-w
   PubMed Web of Science ®Google Scholar
• Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Prato SD. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519–1529. doi:10.1016/S0140-6736(19)32131-2
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853. doi:10.1016/S0140-6736(98)07019-6
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443. doi:10.1056/NEJMoa066224
   PubMed Web of Science ®Google Scholar
• Cherukuri L, Smith MS, Tayek JA. The durability of oral diabetic medications: time to A1c baseline and a review of common oral medications used by the primary care provider. Endocrinol Diabetes Metab J. 2018;2:3.
   Google Scholar
• Philis-Tsimikas A, Wysham CH, Hardy E, Han J, Iqbal N. Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: an open-label extension of the DURATION-1 study. J Diabetes Complications. 2019;33(3):223–230. doi:10.1016/j.jdiacomp.2018.11.012
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Kahn SE, et al. Rationale and design of the gly-cemia reduction approaches in diabetes: a comparative effective- ness study (GRADE). Diabetes Care. 2013;36(8):2254–2261. doi:10.2337/dc13-0356
   PubMed Web of Science ®Google Scholar
• Kim NH, Lim S, Kwak SH, et al. Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomized controlled trial. BMJ Open. 2018;8(9):e022448. doi:10.1136/bmjopen-2018-022448
   PubMed Web of Science ®Google Scholar